Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclophosphamide for Systemic Sclerosis Associated Interstitial Lung Disease
NCT01570764Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2013
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cyclophosphamide in interstitial lung disease (ILD), systemic sclerosis (SSc), sponsored by Assistance publique - Hôpitaux de Paris. Started Jan 2013; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
interstitial lung disease (ILD)systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT01570764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01570764.